Tags: Drug.

Casopitant (trade names Rezonic (US) Zunrisa (EU)) is an neurokinin 1 (NK1) receptor antagonist undergoing research for the treatment of chemotherapy-induced nausea and vomiting (CINV). It is currently under development by GlaxoSmithKline (GSK).In July 2008 the company filed a marketing authorisation application with the European Medicines Agency. The application was withdrawn in September 2009 because GSK decided that further safety assessment was necessary.

Casopitant.png
ATC prefix
A04
ATC suffix
AD13
CAS number
414910-27-3
FDA UNII code
3B03KPM27L
IUPAC name
(2S4S)-4-(4-Acetyl-1-piperazinyl)-N-[(1R)-1-[35-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphenyl)-N-methyl-1-piperidinecarboxamide
PubChem
23725089

Loading...

This page contains content from the copyrighted Wikipedia article "Casopitant"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.